Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec With Prophylactic Steroids in Hemophilia A

  • STATUS
    Recruiting
  • End date
    Sep 24, 2026
  • participants needed
    20
  • sponsor
    BioMarin Pharmaceutical
Updated on 24 July 2021

Summary

This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.

Details
Condition Hemophilia, hema, Hemophilia A
Treatment valoctocogene roxaparvovec
Clinical Study IdentifierNCT04323098
SponsorBioMarin Pharmaceutical
Last Modified on24 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Males 18 years of age with hemophilia A and residual FVIII levels 1 IU/dL as evidenced by medical history, at the time of signing the informed consent
Must have been on prophylactic hemophilia therapy for at least 12 months prior to study entry
Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs)
No previous documented history of a detectable FVIII inhibitor, <0.6 Bethesda Units (BU)
Sexually active participants must agree to use an acceptable method of effective contraception. Participants must agree to contraception use for at least 12 weeks post-infusion

Exclusion Criteria

Detectable pre-existing antibodies to the AAV5 capsid. Up to 25% of subjects may have detectable pre-existing AAV5 capsid antibodies, so long as the titer level is below the minimum required dilution (< 20)
Any evidence of active infection or any immunosuppressive disorder; patients with HIV infection and undetectable viral load are not excluded
Significant renal dysfunction or liver dysfunction, infection or history of hepatic malignancy
Evidence of any bleeding disorder not related to hemophilia A
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note